Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
endocrinology
Biotech
Ascendis scores in phase 3 trial, a boost to endocrine portfolio
Ascendis Pharma has its eyes on an NDA application this year after checking off top endpoints in a phase 3 hypoparathyroidism trial of TransCon PTH.
Max Bayer
Mar 14, 2022 11:15am
New phase 3 data paint fuller picture for Horizon's teprotumumab
Apr 26, 2019 2:05pm
Apitope preps Graves’ disease drug for phase 2
Apr 16, 2018 10:40am
Crinetics raises $63.5M for oral acromegaly therapy
Mar 14, 2018 9:10am